# RDEA3170 and Febuxostat Combination Study in Gout Subjects

> **NCT02246673** · PHASE2 · COMPLETED · sponsor: **Ardea Biosciences, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Gout

## Interventions

- **DRUG:** RDEA3170 15 mg
- **DRUG:** RDEA3170 10 mg
- **DRUG:** RDEA3170 2.5
- **DRUG:** RDEA3170 5 mg
- **DRUG:** Febuxostat 40 mg
- **DRUG:** Febuxostat 80 mg

## Key facts

- **NCT ID:** NCT02246673
- **Lead sponsor:** Ardea Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-07
- **Final completion:** 2016-02
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2017-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02246673

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02246673, "RDEA3170 and Febuxostat Combination Study in Gout Subjects". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT02246673. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*